NCT04020237 is a NA clinical trial of Education about particulate matter practice score in COPD, sponsored by Sei Won Lee.

Who is sponsoring NCT04020237?

NCT04020237 is sponsored by Sei Won Lee.

What drugs are being tested in NCT04020237?

Interventions in NCT04020237: Education about particulate matter practice score.

Is NCT04020237 still recruiting?

NCT04020237 is currently status unknown. Last updated 17 July 2019.

Last reviewed 2019-07-17 · How we verify

NCT04020237

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Particulate Matter in Chronic Obstructive Pulmonary Disease Patients

Status unknown NA Last updated 17 July 2019

What this trial tests

NA trial testing Education about particulate matter practice score in COPD in 120 participants. Status unknown.

Timeline

11 July 2019

Primary endpoint
31 December 2020

31 December 2021

Quick facts

Lead sponsor	Sei Won Lee
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	120
Start date	11 July 2019
Primary completion	31 December 2020
Estimated completion	31 December 2021

Drugs / interventions tested

Education about particulate matter practice score

Conditions studied

COPD — all drugs for COPD →

Sponsor

Sei Won Lee

Who can join

Adults 18 to 80, any sex, with COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective study will be conducted in patients with COPD. The investigators will suggest about intervention for preventing in recurrence and aggravation of adult chronic respiratory disease due to exposure to particulate matter.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of particulate matter exposure on patients with COPD and risk reduction through behavioural interventions: the protocol of a prospective panel study.
Park S, Ra SW, Kang SY, Kim HC, et al · · 2020 · cited 9× · PMID 33168558 · DOI 10.1136/bmjopen-2020-039394
Fine particulate matter aggravates smoking induced lung injury via NLRP3/caspase-1 pathway in COPD.
Chung C, Park SY, Huh JY, Kim NH, et al · · 2024 · cited 8× · PMID 38654364 · DOI 10.1186/s12950-024-00384-z

Verify or expand the search:

Other recruiting trials for COPD

Currently open trials in the same condition.

NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04020237 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sei Won Lee
Last refreshed: 17 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04020237.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing